Mayne Pharma Group stock analysis
Mayne Pharma Group (HG6) Stock Price & Analysis
HG6 Stock Chart & Stats
- Day’s Range
- EUR 1.92 - EUR 1.92
- 52-Week Range
- EUR 1.13 - EUR 3.30
- Previous Close
- EUR 1.98
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 165.99M
- Enterprise Value
- EUR 224.67M
- Total Cash (Recent Filing)
- EUR 82.25M
- Total Debt (Recent Filing)
- EUR 43.20M
- Price to Earnings (P/E)
- 10.6
- Beta
- 0.42
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- -0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Balance-sheet Flexibility
Very low leverage gives Mayne Pharma financial flexibility to fund product development, commercial expansion and capacity investment without relying heavily on debt. The substantial equity base also provides resilience if operating volatility persists, supporting strategic execution over the next several quarters.
Women's Health Product Momentum
Growth across key women's health products, combined with broader coverage and the FDA's removal of BIJUVA's black-box warning, strengthens the platform's commercial prospects. These developments can support prescription growth, improve gross margins and deepen Mayne's position in a structurally expanding category.
DistributeRx Platform Expansion
DistributeRx creates a scalable channel for Mayne and third-party products, with early prescriber adoption and substantial planned capacity expansion. Greater control over distribution can broaden market access, improve channel economics and support recurring growth as more manufacturers and products join the platform.
Bears Say
Revenue Decline And Negative Operating Profitability
Falling revenue alongside a negative operating margin indicates that the reported return to net profit has not yet translated into consistently healthy core earnings. Persistent operating losses can constrain reinvestment, reduce earnings visibility and make the broader recovery dependent on cost control and non-operating items.
Underlying EBITDA Contraction
A sharp EBITDA decline weakens the company's operating cushion and shows that revenue and gross-margin improvements have not yet converted into durable bottom-line progress. Higher commercial and study costs may support future growth, but they currently reduce cash-generating capacity and increase execution risk.
Dermatology Competitive And Coverage Pressure
Coverage losses, brand erosion and generic entry can reduce prescription volumes, pricing power and contribution from dermatology products. Because this pressure affects established commercial franchises rather than a single temporary event, it may require higher spending or portfolio changes to preserve margins through FY2027.
HG6 FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
What is Mayne Pharma Group’s market cap?
When is Mayne Pharma Group’s upcoming earnings report date?
How were Mayne Pharma Group’s earnings last quarter?
Is Mayne Pharma Group overvalued?
Does Mayne Pharma Group pay dividends?
What is Mayne Pharma Group’s EPS estimate?
How many shares outstanding does Mayne Pharma Group have?
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mayne Pharma Group?
What is the TipRanks Smart Score and how is it calculated?
Mayne Pharma Group Stock Smart Score
Company Description
Mayne Pharma Group
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Aaron Gray
- Employees
- 363
- Website
- www.maynepharma.com
- Address
- 1538 Main North Road, Salisbury South, SA, 5106, AU
Mayne Pharma Group (HG6) Earnings & Revenues
HG6 Company Deck
HG6 Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed picture: clear operational progress (notably gross margin expansion, successful DistributeRx launch and dermatology margin improvement) and meaningful product‑level growth in women's health (NEXTSTELLIS, BIJUVA, IMVEXXY). However, these positives were offset by weaker headline revenue (‑6%), a 27% decline in underlying EBITDA, significant one‑off and litigation‑related costs, an $11M impact from ANNOVERA returns, and a decline in international contribution (‑38%). Management highlighted a path to margin improvement and capacity expansion that support future upside, but near‑term financial pressures and legal distractions temper the outlook.
View all DE:HG6 earnings summariesHG6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 11 | 0 | 1 |
